Compare Sirius XM Holdings Inc (SIRI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sirius XM Holdings Inc vs TG Therapeutics Inc — how do they compare? Sirius XM Holdings Inc trades at $28.71 (market cap $9.71B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: Sirius XM Holdings Inc and TG Therapeutics Inc are close in size by market cap, and Sirius XM Holdings Inc pays a 3.75% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SIRI | TGTX | |
|---|---|---|
Market Cap | $9.71B | $8.53B |
Sector | Media | Health |
52-Week High | $32.59 | $59.06 |
52-Week Low | $19.92 | $26.94 |
Enterprise Value | $18.99B | $8.74B |
Dividend Yield | 3.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sirius XM Holdings Inc. (SIRI) trades at $28.80, down 0.66% today, with a bullish technical signal from moving averages and a consensus analyst price target of $34.86. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025 and Q2 2026. Financials show a net income margin of 10.23% for 2025, with revenue at $8.56B, while the balance sheet indicates a debt-to-asset ratio improvement to 35.63% in 2025. Recent news highlights a YouTube partnership expected to boost EBITDA by 2029.
The outlook for SIRI is positive, supported by analyst upgrades and institutional buying, but risks include competitive pressures in audio streaming and reliance on advertising growth. The stock's valuation metrics, such as a P/E of 11.57 and P/B of 0.82, suggest potential upside if earnings improve, though volatility from market sentiment remains a concern.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
